author-photo

Claus Hanusch

147

Papers

6834

Citations

Citation Trend

Filter By

Papers (147) Sort By

JournalConferenceOthers

Quality of Life Effects of an Oral Fixed Combination of Netupitant and Palonosetron in Chemotherapy-Induced Nausea and Vomiting Prevention: Real-World Evidence in Patients with Breast Cancer Receiving Anthracycline-Cyclophosphamide-Based Chemotherapy

2021 Breast Care
Show All
- Source
- Cite
- Save
Citations (0)
Validation of the 21-Gene Recurrence Score Assay in Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer and 0 to 3 Positive Lymph Nodes – Risk Pattern and Outcomes on a Community Level

2021 Breast Care
Show All
- Source
- Cite
- Save
Citations (0)
Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer.

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (4)
Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (11)
Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy.

2021 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
199TiP Phase III post-neoadjuvant study evaluating sacituzumab govitecan (SG), an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Congruence and trajectories of device-measured and self-reported physical activity during therapy for early breast cancer

2021 Breast Cancer Research and Treatment
Show All
- Source
- Cite
- Save
Citations (0)
Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer: The REACT Randomized Clinical Trial.

2021 JAMA Oncology
Show All
- Source
- Cite
- Save
Citations (2)
66P Baseline menopausal status, Ki-67 and stromal tumour-infiltrating lymphocytes (TILs) and association with outcome in triple-negative breast cancer (TNBC): Exploratory analysis in GeparSixto

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer

2021 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (0)

© Copyright 2015-2020 Acemap, Inc. Shanghai Jiao Tong University.

沪ICP备18028330号